28 April 2026 – SinoMab BioScience Limited (SinoMab Bio-B, 03681) has dispatched a circular convening its 2026 Annual General Meeting for 12 June 2026, 10:00 a.m., at Fairmont House, Central, Hong Kong.

Key proposals to be put to shareholders are as follows:

1. Board composition • Re-election of four retiring directors: independent non-executives Dr Chi Ming Lee, Ms Chi Sau Giselle Lee and Mr Nan Shen, plus non-executive Dr Jianmin Zhang. • Election of Ms Lei Xue as non-executive director upon nomination by shareholder group Apricot Entities (aggregate holding >5%). If approved, her three-year term will start on the AGM date; she will not receive director’s fees. • All independent non-executive directors have been assessed as meeting Hong Kong Listing Rules’ independence criteria.

2. Share repurchase mandate • Directors seek renewal of authority to repurchase up to 10% of issued shares (excluding any treasury shares), equal to 138.66 million shares based on the current issued share capital of 1.39 billion shares. • The board states it has no immediate plan to exercise the mandate. Repurchases will be funded from legally available resources and conducted within Listing Rule limits. • Post-buy-back, the largest shareholder, Hainan Haiyao Co., Ltd. (11.46% stake), would hold approximately 12.73% if the mandate were exercised in full—below the 30% threshold that would trigger a mandatory general offer under the Takeovers Code.

3. General issuance mandate • Directors request authority to issue, allot or transfer up to 20% of issued shares (excluding treasury shares), representing 277.33 million shares, with an additional “extension” allowing the aggregate number to be increased by shares repurchased under the above mandate. • The company currently has no definitive plan to issue new shares.

4. Other matters • Re-appointment of Ernst & Young as external auditor and authorisation for the board to fix its remuneration. • Shareholders recorded as at 8 June 2026 will be eligible to attend and vote; the register closes 9–12 June 2026. • Proxy forms must be lodged by 10 June 2026, 10:00 a.m.

No refreshments or corporate souvenirs will be provided at the AGM. A poll will be demanded for all resolutions in accordance with the Listing Rules, with results released via the Hong Kong Stock Exchange and the company’s website.